Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Depreciation & Amortization (IS)EBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Quantum Biopharma (QNTM) Accumulated Depreciation & Amortization (2019 - 2022)

Quantum Biopharma's Accumulated Depreciation & Amortization history spans 4 years, with the latest figure at $4.5 million for Q4 2022.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 12.16% to $4.5 million in Q4 2022 year-over-year; TTM through Dec 2022 was $4.5 million, a 12.16% increase, with the full-year FY2022 number at $4.5 million, up 12.16% from a year prior.
  • Accumulated Depreciation & Amortization hit $4.5 million in Q4 2022 for Quantum Biopharma, up from $4.0 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for QNTM hit a ceiling of $4.5 million in Q4 2022 and a floor of $1.9 million in Q4 2019.
  • Historically, Accumulated Depreciation & Amortization has averaged $3.6 million across 4 years, with a median of $4.0 million in 2020.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: soared 100.74% in 2020 and later rose 3.72% in 2021.
  • Tracing QNTM's Accumulated Depreciation & Amortization over 4 years: stood at $1.9 million in 2019, then soared by 100.74% to $3.9 million in 2020, then rose by 3.72% to $4.0 million in 2021, then rose by 12.16% to $4.5 million in 2022.
  • Business Quant data shows Accumulated Depreciation & Amortization for QNTM at $4.5 million in Q4 2022, $4.0 million in Q4 2021, and $3.9 million in Q4 2020.